Premium
Statistical Evaluation of the Effect of Gemfibrosil, a Cholesterol Reducing Drug, on Some Biochemical Coronary Heart Disease Risk Variables
Author(s) -
Bartkowiak A.,
Łsukasik S.,
Chwistecki K.
Publication year - 1991
Publication title -
biometrical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 63
eISSN - 1521-4036
pISSN - 0323-3847
DOI - 10.1002/bimj.4710330612
Subject(s) - coronary heart disease , medicine , cholesterol , drug , uric acid , regression analysis , cardiology , pharmacology , statistics , mathematics
Abstract The evaluation is based on the clinic trial with gemfibrosil (“Gevilon”, Parke‐Davis) carried out in a group of 48 patients, to whom the drug was administered in the single dose of 900 mg daily during the period of 3 months. In this paper we show the results of the treatment on five biochemical Coronary Heart Disease (CHD) risk variables: Cholesterol (CHOL), High Density Lipoprotein (HDL), Triglyccrides (TGL), Uric Acid (UA) and Glucose (GL). We are concerned with a statistical model allowing to predict which and how large changes in the considered variable can be expected in a patient taking the drug. This is done considering the “regression to the mean” effect.